#antibiotics

#antibiotics

Gepotidacin is a promising new antibiotic for treating gonorrhoea, effectively targeting emerging drug-resistant strains as reported in The Lancet.

A new antibiotic, gepotidacin, has been identified as a promising treatment for gonorrhoea, addressing the rise of drug-resistant strains.

Early-life antibiotic exposure negatively impacts vaccine-induced immune responses in infants.

Antimicrobial resistance poses a serious global health threat, endangering routine medical procedures and leading to rising mortality rates, especially among the elderly.

Improving access to high-quality antibiotics in low- and middle-income countries can significantly combat antimicrobial resistance and save millions of lives.

Loss of antibiotics would lead to disastrous consequences for modern medicine.

Antimicrobial resistance is mainly about pathogens evolving, not individual resistance.

The UK is among the top performers in combating antimicrobial resistance despite slow progress on targets.

The Firstline app enhances antibiotic prescribing practices among clinicians, supporting better health outcomes and infection control.

Antibiotics pose a risk of developing antimicrobial resistance, leading to challenging future infections.

Prescription medications effectively target the root cause of infections, ensuring complete recovery and minimising risks.

Doxycycline is a vital antibiotic that alleviates symptoms and prevents complications, highlighting targeted care.

Antibiotics are essential for quick treatment of bacterial infections with proven success rates.

Antibiotics can significantly disrupt gut health, impacting fetal development during pregnancy.

Dietary attention can help restore gut health after antibiotic use.

Antibiotics may reduce gut microbial diversity but recovery is typically achievable.

Good bacteria can survive antibiotic treatment, aiding microbiome recovery.

Brain infections caused by fungi or bacteria may lead to some dementia cases and even allow for symptom reversal in certain patients.

Struggling with a severe infection, Johan Paulsson initiated a $104-million project, DARTS, to combat antibiotic resistance through innovative solutions.